Natera, Inc. is a diagnostics company, which is focused on the development and commercialization of molecular testing services, applying its technology in the fields of women’s health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening, Spectrum Preimplantation Genetics, Anora Miscarriage Test, Empower, and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Company’s algorithms and bioinformatics in order to validate and launch tests based on the Company’s technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother.
BörsenkürzelNTRA
Name des UnternehmensNatera Inc
IPO-datumJul 02, 2015
CEOMr. Steven Leonard (Steve) Chapman
Anzahl der mitarbeiter4424
WertpapierartOrdinary Share
GeschäftsjahresendeJul 02
Addresse13011 Mccallen Pass
StadtAUSTIN
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl78753
Telefon16502499090
Websitehttps://www.natera.com/
BörsenkürzelNTRA
IPO-datumJul 02, 2015
CEOMr. Steven Leonard (Steve) Chapman
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten